Terms: = Ovarian cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692
39 results:
1. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract] [Full Text] [Related]
2. Expression and prognostic role of stat5a across cancer types.
Maninang C; Li J; Li WX
Biosci Rep; 2023 Aug; 43(8):. PubMed ID: 37369132
[TBL] [Abstract] [Full Text] [Related]
3. [Activation of JAK/STAT in ovarian high-grade serous cancers and its prognostic significance].
Yang J; DU J; Wang YX; Liu CR
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):270-275. PubMed ID: 37042137
[TBL] [Abstract] [Full Text] [Related]
4. PDP1 Promotes Cell Malignant Behavior and Is Associated with Worse Clinical Features in ovarian cancer Patients: Evidence from Bioinformatics and In Vitro Level.
Song Y; Zhang J; Zhang L; Zhang S; Shen C
Comput Math Methods Med; 2022; 2022():7397250. PubMed ID: 36276992
[TBL] [Abstract] [Full Text] [Related]
5. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.
Chen J; Chen S; Dai X; Ma L; Chen Y; Bian W; Sun Y
Front Immunol; 2022; 13():1007326. PubMed ID: 36189254
[TBL] [Abstract] [Full Text] [Related]
6. Herpesvirus entry mediator regulates the transduction of Tregs via stat5/Foxp3 signaling pathway in ovarian cancer cells.
Shan Y; Zhang B; Chen L; Zhang H; Jiang C; You Q; Li Y; Han H; Zhu J
Anticancer Drugs; 2023 Jan; 34(1):73-80. PubMed ID: 35946515
[TBL] [Abstract] [Full Text] [Related]
7. ovarian cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
[TBL] [Abstract] [Full Text] [Related]
8. IFN-γ inhibits ovarian cancer progression via SOCS1/JAK/STAT signaling pathway.
Gao AH; Hu YR; Zhu WP
Clin Transl Oncol; 2022 Jan; 24(1):57-65. PubMed ID: 34275119
[TBL] [Abstract] [Full Text] [Related]
9. Combined Poziotinib with Manidipine Treatment Suppresses ovarian cancer Stem-Cell Proliferation and Stemness.
Lee H; Kim JW; Lee DS; Min SH
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036254
[TBL] [Abstract] [Full Text] [Related]
10. Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated stat5 pathway.
Lee H; Kim JW; Choi DK; Yu JH; Kim JH; Lee DS; Min SH
Biochem Biophys Res Commun; 2020 May; 526(1):158-164. PubMed ID: 32201081
[TBL] [Abstract] [Full Text] [Related]
11. AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.
Trillo-Tinoco J; Sierra RA; Mohamed E; Cao Y; de Mingo-Pulido Á; Gilvary DL; Anadon CM; Costich TL; Wei S; Flores ER; Ruffell B; Conejo-Garcia JR; Rodriguez PC
Cancer Res; 2019 Oct; 79(19):5034-5047. PubMed ID: 31409640
[TBL] [Abstract] [Full Text] [Related]
12. An in vivo half-life extended prolactin receptor antagonist can prevent stat5 phosphorylation.
Yu S; Alkharusi A; Norstedt G; Gräslund T
PLoS One; 2019; 14(5):e0215831. PubMed ID: 31063493
[TBL] [Abstract] [Full Text] [Related]
13. Deletion of Cdkn1b in ACI rats leads to increased proliferation and pregnancy-associated changes in the mammary gland due to perturbed systemic endocrine environment.
Ding L; Shunkwiler LB; Harper NW; Zhao Y; Hinohara K; Huh SJ; Ekram MB; Guz J; Kern MJ; Awgulewitsch A; Shull JD; Smits BMG; Polyak K
PLoS Genet; 2019 Mar; 15(3):e1008002. PubMed ID: 30893315
[TBL] [Abstract] [Full Text] [Related]
14. Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.
Karthikeyan S; Russo A; Dean M; Lantvit DD; Endsley M; Burdette JE
Cancer Lett; 2018 Oct; 433():221-231. PubMed ID: 29981811
[TBL] [Abstract] [Full Text] [Related]
15. Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
Zhou W; Sun W; Yung MMH; Dai S; Cai Y; Chen CW; Meng Y; Lee JB; Braisted JC; Xu Y; Southall NT; Shinn P; Huang X; Song Z; Chen X; Kai Y; Cai X; Li Z; Hao Q; Cheung ANY; Ngan HYS; Liu SS; Barak S; Hao J; Dai Z; Tzatsos A; Peng W; Pei H; Han Z; Chan DW; Zheng W; Zhu W
Oncogene; 2018 Jul; 37(29):3981-3997. PubMed ID: 29662190
[TBL] [Abstract] [Full Text] [Related]
16. The prognostic values of signal transducers activators of transcription family in ovarian cancer.
Li S; Sheng B; Zhao M; Shen Q; Zhu H; Zhu X
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28536310
[TBL] [Abstract] [Full Text] [Related]
17. Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol.
Chen KE; Bustamante K; Nguyen V; Walker AM
Oncotarget; 2017 May; 8(22):36368-36382. PubMed ID: 28422740
[TBL] [Abstract] [Full Text] [Related]
18. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
Hampras SS; Sucheston-Campbell LE; Cannioto R; Chang-Claude J; Modugno F; Dörk T; Hillemanns P; Preus L; Knutson KL; Wallace PK; Hong CC; Friel G; Davis W; Nesline M; Pearce CL; Kelemen LE; Goodman MT; Bandera EV; Terry KL; Schoof N; Eng KH; Clay A; Singh PK; Joseph JM; Aben KK; Anton-Culver H; Antonenkova N; Baker H; Bean Y; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Cook LS; Cramer DW; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Despierre E; Dicks E; Doherty JA; du Bois A; Dürst M; Easton D; Eccles D; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Gronwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hogdall C; Hogdall E; Hosono S; Iversen ES; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kellar M; Kelley JL; Kiemeney LA; Klapdor R; Kolomeyevskaya N; Krakstad C; Kjaer SK; Kruszka B; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Liu S; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Moes-Sosnowska J; Narod SA; Nedergaard L; Nevanlinna H; Nickels S; Olson SH; Orlow I; Weber RP; Paul J; Pejovic T; Pelttari LM; Perkins B; Permuth-Wey J; Pike MC; Plisiecka-Halasa J; Poole EM; Risch HA; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schmitt K; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Tangen IL; Teo SH; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; Tyrer J; van Altena AM; Vergote I; Vierkant RA; Walsh C; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Gayther SA; Ramus SJ; Sellers TA; Schildkraut JM; Phelan CM; Berchuck A; Chenevix-Trench G; Cunningham JM; Pharoah PP; Ness RB; Odunsi K; Goode EL; Moysich KB
Oncotarget; 2016 Oct; 7(43):69097-69110. PubMed ID: 27533245
[TBL] [Abstract] [Full Text] [Related]
19. Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Tavallai M; Booth L; Roberts JL; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(14):17290-300. PubMed ID: 26981780
[TBL] [Abstract] [Full Text] [Related]
20. Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
Chen KE; Walker AM
Cancer Lett; 2016 Jun; 375(2):293-302. PubMed ID: 26970274
[TBL] [Abstract] [Full Text] [Related]
[Next]
